Lisa A. Carey, MD, of UNC Lineberger Comprehensive Cancer Center, offers her thoughts on abstract S1-09, "A phase IB study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer," presented by Rita Nanda, MD.
Larry Wickerham, MD, and Charles E. Geyer, Jr., MD, FACP, take a closer look at the results from the NSABP B-36 and SOFT Trials.
Edith A. Perez, MD, of the Mayo Clinic Cancer Center, discusses abstract S1-06, “Stromal tumor-infiltrating lymphocytes: In the Alliance N9831 trial S-TILs are associated with chemotherapy benefit but not associated with trastuzumab benefit.”
Larry Wickerham, MD, and Harry D. Bear, MD, PhD, discuss three clinical trials:
• B-40, the only study to combine neoadjuvant and adjuvant chemotherapy with bevacizumab
• B-51, on radiation to the chest wall
• Alliance trial, on lymph node dissection
William M. Sikov, MD, of Women and Infants Hospital, discusses abstract S4-05, "Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response rates in triple-negative breast cancer after neoadjuvant chemotherapy with or without carboplatin or bevacizumab: CALGB 40603/150709 (Alliance)."
Charles E. Geyer, Jr, MD, FACP, of Massey Cancer Center, discusses abstract S3-08, “Randomized comparison of adjuvant tamoxifen plus ovarian function suppression vs tamoxifen in premenopausal women with hormone receptor–positive early breast cancer: Analysis of the SOFT trial,” presented by Prudence Francis, MD.
